CEL-SCI Corporation (CEL-SCI) is engaged in the business of Multikine cancer therapy; new cold fill manufacturing service to the pharmaceutical industry, and LEAPS technology, with two products: H1N1, a swine flu treatment for H1N1 hospitalized patients and CEL-2000, a rheumatoid arthritis treatment vaccine. It simulates the activities of a healthy person's immune system, which battles cancer every day. Multikine is multi-targeted. It is the cancer immunotherapy that both kills cancer cells and activates the general immune system to destroy the cancer.